Azacitidine in Patients with Acute Myeloid Leukemia: Impact of Intermediate-Risk Vs High-Risk Cytogenetics on Patient Outcomes
Pleyer, L; Burgstaller, S; Stauder, R; Girschikofsky, M; Linkesch, W; Pfeilstocker, M; Autzinger, EM; Tinchon, C; Sliwa, T; Lang, A; Sperr, WR; Geissler, D; Krippl, P; Voskova, D; Rossmann, DH; Schlick, K; Thaler, J; Halter, B; Machherndl-Spandl, S; Theiler, G; Valent, P; Eckmullner, O; Greil, R BLOOD. 2014; 124(21):
Azacitidine in Acute Myeloid Leukemia: Comparison of Patients with AML-MRF Vs AML-NOS Enrolled in the Austrian Azacitidine Registry
Pleyer, L; Burgstaller, S; Stauder, R; Girschikofsky, M; Linkesch, W; Pfeilstocker, M; Autzinger, EM; Tinchon, C; Sliwa, T; Lang, A; Sperr, WR; Geissler, D; Krippl, P; Voskova, D; Rossmann, DH; Schlick, K; Thaler, J; Halter, B; Machherndl-Spandl, S; Theiler, G; Valent, P; Eckmullner, O; Greil, R BLOOD. 2014; 124(21):
CXCL12 Enhances CLL Cell and T-Cell Migration in a Dynamic Circulating Model of CLL That Can be Abrogated By the CXCR4 Antagonist ONO-7161
Walsby, EJ; Brennan, P; Pratt, G; Hartmann, TN; Yoshizawa, T; Fegan, C; Pepper, C BLOOD. 2014; 124(21):
The Transcription Factor IRF4 Is Crucial for CLL Progression and Regulates Survival and Proliferation in a Microenvironment Related Manner
Asslaber, D; Hofbauer, JP; Zaborsky, N; Flenady, S; Hartmann, TN; Greil, R; Egle, A BLOOD. 2014; 124(21):
A Complementary Role of High Throughput Sequencing and Multiparameter Cytometry for Minimal Residual Disease (MRD) Detection in Chronic Lymphocytic Leukemia (CLL):an European Research Initiative (ERIC) Study
Rawstron, A; Fazi, C; Villamor, N; Delgado, J; Letestu, R; Cymbalista, F; Palacio, C; Bosch, F; De Tute, RM; Liptrot, S; OxxxBrien, D; Spacek, M; Dobber, J; Kater, AP; Gambell, PC; Westerman, DA; Soosapilla, A; Mulligan, SP; Lozanski, G; Lin, K; Pettitt, AR; Brachtl, G; Egle, A; Williamson, DW; Sanders, CM; Robins, H; Boysen, J; Shanafelt, TD; Hanson, CA; Jorgensen, JL; Wierda, WG; Yuan, C; Stetler-Stevenson, M; Rassenti, L; Broome, HE; Kipps, TJ; Hauwel, M; Marinov, I; Craig, FE; Josep, N; Moreno, C; Stehlikova, O; Doubek, M; Pospisilova, S; Kreuzer, KA; Hallek, M; Hillmen, P; Montserrat, E; Ghia, P BLOOD. 2014; 124(21):
Switch from Every Two Weeks to Every Four Weeks Administration Schedule of AOP2014, an Innovative Pegylated Interferon Alpha, in Polycythemia Very Patients Allows Maintaining of Efficacy with Improved Toxicity Profile in Phase I/II Study
Gisslinger, H; Buxhofer-Ausch, V; Thaler, J; Schloegl, E; Gastl, GA; Wolf, D; Kralovics, R; Gisslinger, B; Strecker, K; Egle, A; Melchardt, T; Burgstaller, S; Willenbacher, E; Zoerer, M; Kadlecova, P; Zagrijtschuk, O; Klade, C; Greil, R BLOOD. 2014; 124(21):
Rituximab Maintenance after Chemoimmunotherapy Induction in 1st and 2st Line Improves Progression Free Survival: Planned Interim Analysis of the International Randomized AGMT-CLL8/a Mabtenance Trial
Greil, R; Obrtlikova, P; Smolej, L; Kozak, T; Steurer, M; Andel, J; Thaler, J; Mikuskova, E; Gercheva, L; Nosslinger, T; Ladicka, M; Girschikofsky, M; Hrubiko, M; Jager, U; Fridrik, MA; Pecherstorfer, M; Kralikova, E; Burcoveanu, C; Goranov, S; Jurkovikova, J; Petzer, AL; Mihaylov, GG; Raynov, J; Oexle, H; Zabernigg, A; Flochova, E; Palasthy, S; Melchardt, T; Mayer, J; Egle, A BLOOD. 2014; 124(21):
Azacitidine in Patients with Acute Myeloid Leukemia: Assessing the Potential Negative Impact of Elevated Baseline White Blood Cell Count on Outcome
Pleyer, L; Burgstaller, S; Stauder, R; Girschikofsky, M; Linkesch, W; Pfeilstocker, M; Autzinger, EM; Tinchon, C; Sliwa, T; Lang, A; Sperr, WR; Geissler, D; Krippl, P; Voskova, D; Rossmann, DH; Schlick, K; Thaler, J; Halter, B; Machherndl-Spandl, S; Theiler, G; Valent, P; Eckmullner, O; Greil, R BLOOD. 2014; 124(21):
Azacitidine in Patients with Relapsed/Refractory Acute Myeloid Leukemia : Retrospective Analysis of the Austrian Azacitidine Registry
Pleyer, L; Burgstaller, S; Stauder, R; Girschikofsky, M; Linkesch, W; Pfeilstocker, M; Autzinger, EM; Tinchon, C; Sliwa, T; Lang, A; Sperr, WR; Geissler, D; Krippl, P; Voskova, D; Rossmann, DH; Schlick, K; Thaler, J; Halter, B; Machherndl-Spandl, S; Theiler, G; Valent, P; Eckmullner, O; Greil, R BLOOD. 2014; 124(21):
Targeting Dysfunctional Myeloid Cells Delays Disease Development and Improves Immune Function in a CLL Mouse Model
Hanna, B; McClanahan, F; Zaborsky, N; Durr, C; Kalter, V; Egle, A; Gribben, JG; Lichter, P; Seiffert, M BLOOD. 2014; 124(21):